Ara mostrant els elements 1-5 de 5
Cañadas Castillo, Israel (Data de defensa: 2013-06-25)
Small cell lung carcinoma (SCLC) is a highly lethal disease due to its chemorefractory nature after first line treatment. The mechanisms to overcome this resistance have remained elusive to tackle up ...
Guardia Valenzuela, Cristina (Data de defensa: 2019-12-19)
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el ...
Soria Jiménez, Luis (Data de defensa: 2023-02-17)
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...
García Parra, Jetzabel (Data de defensa: 2012-06-21)
Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of ...
Dalmases Massegú, Alba (Data de defensa: 2012-06-22)
EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal ...